Spinocerebellar ataxia type 2: Measures of saccade changes improve power for clinical trials - PubMed (original) (raw)
doi: 10.1002/mds.26532. Epub 2016 Feb 5.
Affiliations
- PMID: 26846400
- DOI: 10.1002/mds.26532
Spinocerebellar ataxia type 2: Measures of saccade changes improve power for clinical trials
Roberto Rodríguez-Labrada et al. Mov Disord. 2016 Apr.
Abstract
Background: Saccadic eye movement abnormalities are common in patients with spinocerebellar ataxia type 2, but it is unclear how these alterations progress over time. The aim of this study was to assess the progression of saccade involvement in spinocerebellar ataxia type 2 patients, identify its main determinants, and evaluate its usefulness as outcome measures in clinical trials.
Methods: A prospective 5-year follow-up study was performed with 30 spinocerebellar ataxia type 2 patients and their matched healthy controls, who were evaluated a total of four times by clinical and electrooculographical assessments of horizontal saccades and by the scoring of ataxia.
Results: Patients showed significant decreases in saccade peak velocity and saccade accuracy as well as increases of saccadic latency during the follow-up period. Annual progression rates were significantly higher in patients compared to controls. Faster progression rates of saccade slowing were associated with higher trinucleotide cytosine-adenine-guanine repeat expansions. Sample-size estimates for two-arm trials would require 19 patients per group to detect a 50% reduction in disease progression using saccade peak velocity as outcome variable, but 44 and 124 patients using saccade latency and accuracy, respectively (power, 80%; alpha = 0.05).
Conclusions: Electrooculographical measures of saccade changes are useful for the objective quantification of disease course in spinocerebellar ataxia type 2. The progression rate of saccade slowing is influenced by the expansion size, providing novel insight into the cumulative polyglutamine neurotoxicity, and supporting the usefulness of saccade peak velocity as a sensitive biomarker during the natural history of the disease, and as suitable outcome measure for therapeutic trials.
Keywords: SCA2; clinical trials; longitudinal study; saccade slowing; saccadic eye movements; spinocerebellar ataxias.
© 2016 International Parkinson and Movement Disorder Society.
Similar articles
- Saccade velocity is reduced in presymptomatic spinocerebellar ataxia type 2.
Velázquez-Pérez L, Seifried C, Abele M, Wirjatijasa F, Rodríguez-Labrada R, Santos-Falcón N, Sánchez-Cruz G, Almaguer-Mederos L, Tejeda R, Canales-Ochoa N, Fetter M, Ziemann U, Klockgether T, Medrano-Montero J, Rodríguez-Díaz J, Laffita-Mesa JM, Auburger G. Velázquez-Pérez L, et al. Clin Neurophysiol. 2009 Mar;120(3):632-5. doi: 10.1016/j.clinph.2008.12.040. Epub 2009 Feb 7. Clin Neurophysiol. 2009. PMID: 19201647 - Differences in saccade dynamics between spinocerebellar ataxia 2 and late-onset cerebellar ataxias.
Federighi P, Cevenini G, Dotti MT, Rosini F, Pretegiani E, Federico A, Rufa A. Federighi P, et al. Brain. 2011 Mar;134(Pt 3):879-91. doi: 10.1093/brain/awr009. Brain. 2011. PMID: 21354979 - Saccade velocity as a surrogate disease marker in spinocerebellar ataxia type 2.
Seifried C, Velázquez-Pérez L, Santos-Falcón N, Abele M, Ziemann U, Almaguer LE, Martínez-Góngora E, Sánchez-Cruz G, Canales N, Pérez-González R, Velázquez-Manresa M, Viebahn B, Stuckrad-Barre S, Klockgether T, Fetter M, Auburger G. Seifried C, et al. Ann N Y Acad Sci. 2005 Apr;1039:524-7. doi: 10.1196/annals.1325.059. Ann N Y Acad Sci. 2005. PMID: 15827014 - Neurophysiological features in spinocerebellar ataxia type 2: Prospects for novel biomarkers.
Velázquez-Pérez L, Rodríguez-Labrada R, González-Garcés Y, Vázquez-Mojena Y, Pérez-Rodríguez R, Ziemann U. Velázquez-Pérez L, et al. Clin Neurophysiol. 2022 Mar;135:1-12. doi: 10.1016/j.clinph.2021.12.005. Epub 2021 Dec 23. Clin Neurophysiol. 2022. PMID: 34998091 Review. - Eye movement abnormalities correlate with genotype in autosomal dominant cerebellar ataxia type I.
Rivaud-Pechoux S, Dürr A, Gaymard B, Cancel G, Ploner CJ, Agid Y, Brice A, Pierrot-Deseilligny C. Rivaud-Pechoux S, et al. Ann Neurol. 1998 Mar;43(3):297-302. doi: 10.1002/ana.410430306. Ann Neurol. 1998. PMID: 9506545 Review.
Cited by
- Spinocerebellar ataxias: prospects and challenges for therapy development.
Ashizawa T, Öz G, Paulson HL. Ashizawa T, et al. Nat Rev Neurol. 2018 Oct;14(10):590-605. doi: 10.1038/s41582-018-0051-6. Nat Rev Neurol. 2018. PMID: 30131520 Free PMC article. Review. - The progression rate of spinocerebellar ataxia type 3 varies with disease stage.
Peng L, Peng Y, Chen Z, Wang C, Long Z, Peng H, Shi Y, Shen L, Xia K, Leotti VB, Jardim LB, Tang B, Qiu R, Jiang H. Peng L, et al. J Transl Med. 2022 May 14;20(1):226. doi: 10.1186/s12967-022-03428-1. J Transl Med. 2022. PMID: 35568848 Free PMC article. - A Review of Ocular Movement Abnormalities in Hereditary Cerebellar Ataxias.
Salari M, Etemadifar M, Rashedi R, Mardani S. Salari M, et al. Cerebellum. 2024 Apr;23(2):702-721. doi: 10.1007/s12311-023-01554-0. Epub 2023 Mar 31. Cerebellum. 2024. PMID: 37000369 Review. - Quantitative Oculomotor Assessment in Hereditary Ataxia: Discriminatory Power, Correlation with Severity Measures, and Recommended Parameters for Specific Genotypes.
Garces P, Antoniades CA, Sobanska A, Kovacs N, Ying SH, Gupta AS, Perlman S, Szmulewicz DJ, Pane C, Németh AH, Jardim LB, Coarelli G, Dankova M, Traschütz A, Tarnutzer AA. Garces P, et al. Cerebellum. 2024 Feb;23(1):121-135. doi: 10.1007/s12311-023-01514-8. Epub 2023 Jan 14. Cerebellum. 2024. PMID: 36640220 Free PMC article. - Voxel-based meta-analysis of gray and white matter volume abnormalities in spinocerebellar ataxia type 2.
Han Q, Yang J, Xiong H, Shang H. Han Q, et al. Brain Behav. 2018 Sep;8(9):e01099. doi: 10.1002/brb3.1099. Epub 2018 Aug 20. Brain Behav. 2018. PMID: 30125476 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials